EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells

Molecular Cancer Therapeutics

Volumn 8, Issue 7, 2009, Pages 1787-1798

  Bhatia, Vandanajay ^a   Saini, Manjit K ^a   Shen, Xiaoli ^a   Bi, Lian X ^a   Qiu, Suimin ^a   Weigel, Nancy L ^c   Falzon, Miriam ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; PARATHYROID HORMONE RELATED PROTEIN; SEOCALCITOL; VASCULOTROPIN; VITAMIN D DERIVATIVE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; CALCIUM METABOLISM; CANCER CELL CULTURE; CANCER INVASION; CANCER SIZE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; VITAMIN D DEFICIENCY;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CALCITRIOL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, NUDE; PARATHYROID HORMONE-RELATED PROTEIN; PROSTATE; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67651174455     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0064     Document Type: Article

References (50)

1. Sadar MD, Hussain M, Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 1999;6:487-502.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:1873-82.
3. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-83.
4. Rana A, Chisholm GD, Khan M, Sekharjit SS, Merrick MV, Ellton RA. Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate. Br J Urol 1993;72:933-6.
5. Choueiri MB, Tu S-M, Yu-Lee L-Y, Lin S-H. The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev 2006;25:601-9.
6. Berruti A, Piovesan A, Torta M, et al. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiographic appearances and disease extension. Br J Cancer 1996;73:1581-7.
7. Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Res 1996;22:289-331.
8. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213-6s.
9. Keller ET, Zhang J, Cooper CR, et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 2001;20:333-49.
10. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer 1977;80:1581-7.
11. Iwamura M, Wu R, Abrahamsson PA, di Sant'Agnese PA, Cockett AT, Deftos LJ. Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. Urology 1994;43:667-74.
12. Kramer S, Reynolds FJ, Jr., Castillo M, Valenzuela DM, Thorikay M, Sorvillo JM. Immunological identification and distribution of parathyroid hormone-like protein polypeptides in normal and malignant tissues. Endocrinology 1991;128:1927-37.
13. 3. Steroids 2007;72:930-8.
14. Tovar VA, Falzon M. Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways. Reg Pept 2002;105:109-20.
15. Dougherty KM, Blomme EAG, Koh AJ, et al. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res 1999;59:6015-22.
16. Hall CL, Kang S, MacDougals OA, Keller ET. Role of Wnts in prostate cancer bone metastases. J Cell Biochem 2006;97:661-72.
17. De Luca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80:1689-96S.
18. Holick MF. Vitamin D: a millennium perspective. J Cell Biochem 2003;88:296-307.
19. 3 inhibits angiogenesis in vitro and in vivo. Circ Res 2000;87:214-20.
20. Bouillon R, Bischoff-Ferrari H, Willett W. Vitamin D and health: perspectives from mice and man. J Bone Miner Res 2008;23:974-9.
21. Tovar Sepulveda VA, Weigel NL, Falzon M. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. Steroids 2006;71:102-15.
22. El Abdaimi K, Papavasilou V, Rabbani SA, Rhim JS, Goltzmann D, Kremer R. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer. Cancer Res 1999;59:3325-8.
23. Haq M, Kremer R, Goltzman D, Rabbani SA. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J Clin Invest 1993;91:2416-22.
24. Mathiasen IS, Colston KW, Binderup L. EB1089: a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects of cancer cells. J Steroid Biochem Mol Biol 1993;46:365-71.
25. Kissmeyer AM, Binderup E, Binderup L, et al. Metabolism of the vitamin D analog EB1089: identification of in vivo and in vitro liver metabolites and their biological activities. Biochem Pharmacol 1997;53:1087-97.
26. Thalmann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-81.
27. Shen X, Falzon M. PTH-related protein upregulates integrin α6β4 expression and activates Akt in breast cancer cells. Exp Cell Res 2006;312:3822-34.
28. Shen X, Rychahou PG, Evers BM, Falzon M. PTHrP increases xenograft growth and promotes integrin α6β4 expression and Akt activation in colon cancer. Cancer Lett 2007;258:241-52.
29. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res 2000;60:779-82.
30. 4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling. Mol Cancer Res. In press.
31. Lim DJ, Liu X-L, Sutkowski DM, Braun EJ, Lee C, Kozlowski JM. Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice. Prostate 1993;22:109-18.
32. El Abdaimi K, Dion N, Papavasiliou V, et al. The vitamin D analogue EB1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res 2000;60:4412-8.
33. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2005;100:57-70.
34. Eccles SA. Targeting key steps in metastatic tumour progression. Curr Opin Genet Dev 2005;15:77-86.
35. Deftos LJ. Prostate carcinoma: production of bioactive factors. Cancer 2000;88:3002-8.
36. Shaw LM, Rabinovitz I, Wang HH, Toker A, Mercurio AM. Activation of phosphoinositide-3-OH kinase by the α6β4 integrin promotes carcinoma invasion. Cell 1997;91:949-60.
37. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995;1:27-31.
38. Pepper MS. Manipulating angiogenesis: from basic science to the bedside. Arterioscler Thromb Vasc Biol 1997;17:605-19.
39. Bakre MM, Zhu Y, Yin H, et al. Parathyroid hormone-related peptide is a naturally occurring protein kinase A-dependent angiogenesis inhibitor. Nat Med 2002;8:995-1003.
40. Maioli E, Fortino V. The complexity of parathyroid hormone-related protein signalling. Cell Mol Life Sci 2004;61:257-62.
41. Falzon M, Du P. Enhanced growth of MCF-7 breast cancer cells over-expressing parathyroid hormone-related peptide. Endocrinology 2000;141:1882-92.
42. Massfelder T, Dann P, Wu TL, Vasavada R, Helwig J-J, Stewart AF. Opposing mitogenic and antimitogenic actions of parathyroid hormone-related protein in vascular smooth muscle cells: a critical role for nuclear targeting. Proc Natl Acad Sci U S A 1997;94:13630-5.
43. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005;10:169-80.
44. Blomme EAG, Dougherty KM, Pienta KJ, Capen CC, Rosol TJ, McCauley LK. Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein. Prostate 1999;39:187-97.
45. Rabbani SA, Gladu J, Harakidas P, Jamison B, Goltzman D. Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int J Cancer 1999;80:257-64.
46. Deftos LJ, Barken I, Burton DW, Hoffman RM, Geller J. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem Biophys Res Commun 2005;327:468-72.
47. Wu TT, Sikes RA, Cui Q, et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 1998;77:887-94.
48. Sasaki A, Toneda T, Terakado N, Alcalde RE, Suzuki A, Matsumura T. Experimental bone metastasis model of the oral and maxillofacial region. Anticancer Res 1998;18:1579-84.
49. Stewart LV, Weigel NL. Vitamin D and prostate cancer. Exp Biol Med (Maywood) 2004;229:277-84.
50. 3. J Steroid Biochem Mol Biol 2005;97:203-11.